Fulcrum Therapeutics completes $80.9M underwritten public offering

Fulcrum Therapeutics, Inc.

Underwriters exercised option to buy 1,438,618 additional shares at $7.82/share.
Additional net proceeds of ~$10.6M; total net proceeds ~$80.9M after discounts and expenses.
Overallotment option closed on August 23, 2022.

item 8.01

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-227590

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.